TAILoR (TelmisArtan and InsuLin Resistance in Human Immunodeficiency Virus [HIV]): An Adaptive-design, Dose-ranging Phase IIb Randomized Trial of Telmisartan for the Reduction of Insulin Resistance in HIV-positive Individuals on Combination Antiretroviral Therapy. (2020)


No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1093/cid/ciz589

PubMed Identifier: 31425580

Publication URI: http://europepmc.org/abstract/MED/31425580

Type: Journal Article/Review

Volume: 70

Parent Publication: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Issue: 10

ISSN: 1058-4838